root recovery

Root Recovery Proceeds Production Gains

Daniel CooperHLB Management, OTC Expert

root recovery

Sponsored Content

In this special series, Tom Johnson, owner of TJ BioTech, tackles questions about optimizing trunk-injection applications to treat HLB.

Q: There have been some mixed results from OTC injections depending on geography within Florida. Is the citrus industry in Florida experiencing a recovery from the effects of HLB or not?

Tom Johnson: Since the release of ReMedium TI® in January of 2023, the breakthrough of a novel formulation of OTC has allowed millions of trees across Florida to be injected with OTC. The main cause of production decline from HLB is the decline and loss of root structure in the grove. According to University of Florida Professor Emeritus Jim Graham, the decline in production from HLB did not occur first. The decline in roots was happening underground, and the decline in production above ground came later.

So, the recovery is happening, but it has to occur in the root structure below ground first. The production recovery above ground is soon to follow. Again, according to Graham, the root recovery is underway, but the recent hurricanes have reduced root recovery in some areas that were hardest hit by the storms. However, root mass did not decline from hurricane damage as it did before OTC injections.

Recovery is occurring across the state, and the production gains that we all want are happening now in the areas of least hurricane impact. Don’t give up. The best is yet to come.

ReMedium TI® is performing very well, but please take care to protect your formulated ReMedium TI® from damage from ultraviolet light and heat to the best of your ability. Mobility is the key to the best outcome from an OTC injection. Breakdown damage not only reduces the amount of active ingredient in the solution, but it also reduces the mobility of the formulation.

ReMedium TI® has the initial purity, and FLexInject® injection devices offer the best protection from UV and heat. Both are important to the final outcome.

We are making progress.

Tom Johnson is the owner of TJ BioTech, the manufacturer of ReMedium TI®.

Share this Post

Sponsored Content